VIRI News and Press, Virios Therapeutics Inc. From 08/23/21

The following slide deck was published by Virios Therapeutics, Inc. in conjunction with this event. For further details see: Virios Therapeutics (VIRI) Investor Presentation - Slideshow

Data from Ongoing Phase 2b Fibromyalgia Trial Projected for Mid-2022 Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today the expan...

LOS ANGELES, CA / ACCESSWIRE / August 16, 2021 / The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be presenting via virtual webcast to a global investor audience. The SNN Network Summer Virt...

Data from Ongoing Phase 2b Fibromyalgia Trial Projected for Mid-2022 Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Chai...

Virios Therapeutics Inc. (VIRI) Q2 2021 Earnings Conference Call August 12, 2021 8:30 AM ET Company Participants Angela Walsh - SVP of Finance, Secretary & Treasurer Greg Duncan - CEO & Chairman Conference Call Participants David Bautz - Zacks Small-Cap Research Presentation Operator ...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. ...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that an interview with Chairman and CEO, Greg Duncan, was aired on Bloomberg TV during The Red...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, announced today that its second quarter 2021 financial results will be reported on Thursday, August 12, 2021 b...

IMV (IMV) +51%.Tyme Technologies (TYME) +35% granted U.S. patent claims covering use of Tyrosine-based drug delivery method to treat cancerDynatronics (DYNT) +33%.NanoVibronix (NAOV) +33%.Xenetic Biosciences (XBIO) +35% on $12.5M private placementBitfarms  (BITF) +19%.Bit ...